The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.

[1]  M. Jeong,et al.  Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. , 2011, Journal of the American College of Cardiology.

[2]  M. Jacoski,et al.  A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  Takeshi Kimura,et al.  Sirolimus-Eluting Stent Versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry , 2010, Circulation.

[4]  A. Kastrati,et al.  Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.

[5]  A. Kaltoft,et al.  Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. , 2010, The American journal of cardiology.

[6]  J. Sousa,et al.  Comparison of the very long term (>1 year) outcomes of drug-eluting stents for the treatment of bare-metal and drug-eluting stent restenosis. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  Á. Cequier,et al.  Sirolimus‐eluting stents versus bare‐metal stents in patients with in‐stent restenosis: Results of a pooled analysis of two randomized studies , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  P. Chan,et al.  Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. , 2007, The American journal of cardiology.

[9]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[10]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[11]  G. Montalescot,et al.  Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.

[12]  V. Gama-Ribeiro,et al.  Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. , 2005, Journal of the American College of Cardiology.

[13]  J. E. Sousa,et al.  Angiographic and intravascular ultrasound findings of the late catch-up phenomenon after intracoronary beta-radiation for the treatment of in-stent restenosis. , 2005, The Journal of invasive cardiology.

[14]  Seung‐Jung Park,et al.  Comparison of angiographic and clinical outcomes between rotational atherectomy and cutting balloon angioplasty followed by radiation therapy with a rhenium 188-mercaptoacetyltriglycine-filled balloon in the treatment of diffuse in-stent restenosis. , 2005, American Heart Journal.

[15]  D. Simon,et al.  Molecular Basis of Restenosis and Drug-Eluting Stents , 2005, Circulation.

[16]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[17]  Lawrence Joseph,et al.  A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents , 2004, The Lancet.

[18]  C. Macaya,et al.  Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. , 2004, Journal of the American College of Cardiology.

[19]  P. Serruys,et al.  Post–Sirolimus-Eluting Stent Restenosis Treated With Repeat Percutaneous Intervention: Late Angiographic and Clinical Outcomes , 2004, Circulation.

[20]  D. Trabattoni,et al.  Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up. , 2004, Italian heart journal : official journal of the Italian Federation of Cardiology.

[21]  P. Teirstein,et al.  Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions: Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies , 2003, Circulation.

[22]  Muzaffer Degertekin,et al.  TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation , 2003, Circulation.

[23]  Patrick W Serruys,et al.  Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. , 2003, Journal of the American College of Cardiology.

[24]  P. Serruys,et al.  Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2003, Circulation.

[25]  R. Mehran,et al.  Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with diffuse in-stent restenosis. , 2001, The American journal of cardiology.

[26]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[27]  R. Costa,et al.  Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry. , 2010, JACC. Cardiovascular interventions.